Context Therapeutics (NASDAQ:CNTX) Upgraded at Wall Street Zen

Context Therapeutics (NASDAQ:CNTX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

Other equities analysts have also recently issued research reports about the company. HC Wainwright raised their target price on Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. D. Boral Capital reissued a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research note on Thursday, November 6th. Jones Trading initiated coverage on shares of Context Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $6.00.

Context Therapeutics Stock Down 5.3%

NASDAQ:CNTX opened at $2.30 on Monday. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $2.85. The stock’s fifty day simple moving average is $1.65 and its 200-day simple moving average is $1.24. The firm has a market capitalization of $211.32 million, a P/E ratio of -9.58 and a beta of 1.93.

Institutional Investors Weigh In On Context Therapeutics

Large investors have recently made changes to their positions in the stock. Clear Harbor Asset Management LLC raised its holdings in shares of Context Therapeutics by 60.5% during the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock worth $90,000 after acquiring an additional 35,000 shares during the period. Citadel Advisors LLC bought a new stake in shares of Context Therapeutics in the third quarter valued at about $100,000. State Street Corp lifted its holdings in shares of Context Therapeutics by 8.5% in the fourth quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after purchasing an additional 13,000 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Context Therapeutics by 58.8% during the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after buying an additional 188,202 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after buying an additional 134,449 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.